🍽️ clavulanate potassium salt (antibiotic)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Gastrointestinal Effects: Like many antibiotics, amoxicillin/clavulanate potassium can cause gastrointestinal side effects such as nausea, vomiting, diarrhea, and abdominal pain. These symptoms are usually mild and temporary but can sometimes be severe.

  2. Allergic Reactions: Some individuals may experience allergic reactions to amoxicillin/clavulanate potassium, which can manifest as rash, itching, swelling, or difficulty breathing. Severe allergic reactions like anaphylaxis are rare but can occur.

  3. Clostridium difficile Infection: The use of amoxicillin/clavulanate potassium, like other antibiotics, can disrupt the normal balance of bacteria in the gut, leading to the overgrowth of Clostridium difficile bacteria and causing a potentially severe infection known as C. difficile-associated diarrhea.

  4. Liver Problems: Rarely, amoxicillin/clavulanate potassium can cause liver toxicity, leading to elevated liver enzymes or liver damage. Symptoms may include jaundice (yellowing of the skin or eyes), dark urine, or abdominal pain.

  5. Drug Interactions: Amoxicillin/clavulanate potassium can interact with other medications, including certain anticoagulants, oral contraceptives, and medications used to treat gout. These interactions can lead to altered drug levels in the body and potentially serious side effects.

  6. Skin Reactions: Some individuals may develop skin reactions like rash, hives, or photosensitivity (increased sensitivity to sunlight) while taking amoxicillin/clavulanate potassium.

  7. Respiratory Effects: Amoxicillin/clavulanate potassium may rarely cause respiratory side effects such as cough or shortness of breath.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of clavulanate potassium salt (antibiotic) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces

Bacteria Impacted by clavulanate potassium salt (antibiotic)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Odoribacter genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
Blautia genus Decreases 👪 Source Study
Akkermansia genus Decreases 👪 Source Study
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Segatella genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Coprococcus genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
Ruminococcus bromii species Decreases 📓 Source Study
Blautia obeum species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Dorea formicigenerans species Decreases 📓 Source Study
Coprococcus comes species Decreases 📓 Source Study
[Ruminococcus] gnavus species Decreases 📓 Source Study
Roseburia intestinalis species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of clavulanate potassium salt (antibiotic) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0 0
ADHD 1.6 0.4 3
Age-Related Macular Degeneration and Glaucoma 0.6 0.6
Allergic Rhinitis (Hay Fever) 0.4 0.4
Allergies 1.8 2.8 -0.56
Allergy to milk products 0.5 0.5
Alopecia (Hair Loss) 0.9 0.9
Alzheimer's disease 3.2 1.6 1
Amyotrophic lateral sclerosis (ALS) Motor Neuron 2.8 1.5 0.87
Ankylosing spondylitis 1.7 1.3 0.31
Anorexia Nervosa 1.2 -1.2
Antiphospholipid syndrome (APS) 0.4 0 0
Asthma 1.6 -1.6
Atherosclerosis 0.9 2 -1.22
Atrial fibrillation 1.8 0.8 1.25
Autism 5.1 4.3 0.19
Barrett esophagus cancer 0.4 0.4
Bipolar Disorder 0.5 1.1 -1.2
Brain Trauma 0.2 -0.2
Cancer (General) 0.5 0.5
Carcinoma 1.9 1.9 0
Celiac Disease 0.5 2.4 -3.8
Cerebral Palsy 0.5 1.2 -1.4
Chronic Fatigue Syndrome 2.9 4.5 -0.55
Chronic Kidney Disease 0.4 0.6 -0.5
Chronic Lyme 0.2 -0.2
Chronic Obstructive Pulmonary Disease (COPD) 0.4 0.6 -0.5
Chronic Urticaria (Hives) 1.8 -1.8
Coagulation / Micro clot triggering bacteria 1.2 -1.2
Colorectal Cancer 2.5 2.5
Constipation 0.7 -0.7
Coronary artery disease 0.9 0.9 0
COVID-19 4.7 8.4 -0.79
Crohn's Disease 4.6 3.4 0.35
cystic fibrosis 0.2 -0.2
deep vein thrombosis 0.7 -0.7
Depression 2.4 3.9 -0.63
Eczema 0.4 0.4
Endometriosis 1.3 1 0.3
Eosinophilic Esophagitis 0.4 0.4
Epilepsy 1.4 2 -0.43
Fibromyalgia 1.1 1.7 -0.55
Functional constipation / chronic idiopathic constipation 0.9 1.4 -0.56
gallstone disease (gsd) 1.4 0.6 1.33
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.4 1 -1.5
Generalized anxiety disorder 1.3 0.4 2.25
Gout 0.4 -0.4
Graves' disease 1.1 -1.1
Halitosis 0.4 0.4
Hashimoto's thyroiditis 1.6 0 0
Hidradenitis Suppurativa 0.4 0.4
hypercholesterolemia (High Cholesterol) 0.5 1 -1
hyperglycemia 2 -2
Hyperlipidemia (High Blood Fats) 0.5 0.5
hypersomnia 0.5 -0.5
hypertension (High Blood Pressure 1 2.1 -1.1
Hypothyroidism 0.9 -0.9
Hypoxia 0.5 0.5
IgA nephropathy (IgAN) 1.2 -1.2
Inflammatory Bowel Disease 0.4 5.2 -12
Insomnia 0.5 0.2 1.5
Intelligence 0.4 0.8 -1
Intracranial aneurysms 1 1
Irritable Bowel Syndrome 1.7 1.2 0.42
Liver Cirrhosis 3.4 2 0.7
Long COVID 3.1 4.9 -0.58
Low bone mineral density 0.6 -0.6
Lung Cancer 2.4 -2.4
Mast Cell Issues / mastitis 0.9 -0.9
ME/CFS with IBS 2.6 -2.6
ME/CFS without IBS 0.5 1.2 -1.4
Metabolic Syndrome 3.8 4.4 -0.16
Mood Disorders 4.3 3.9 0.1
multiple chemical sensitivity [MCS] 0.5 0.5 0
Multiple Sclerosis 3.3 1.5 1.2
Multiple system atrophy (MSA) 1.5 1 0.5
neuropathic pain 0.5 -0.5
Neuropathy (all types) 1 1
neuropsychiatric disorders (PANDAS, PANS) 0.5 0.5
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 1.7 3.8 -1.24
Obesity 4.7 4.2 0.12
obsessive-compulsive disorder 2 4 -1
Osteoarthritis 0.4 0.5 -0.25
Osteoporosis 0.5 1.5 -2
pancreatic cancer 0.5 0.5
Parkinson's Disease 1.9 2.4 -0.26
Polycystic ovary syndrome 1 2.2 -1.2
Postural orthostatic tachycardia syndrome 0.4 -0.4
Premenstrual dysphoric disorder 0.5 0.5
primary biliary cholangitis 0.4 0.4
Psoriasis 2.3 2.4 -0.04
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 4.6 1.9 1.42
Rosacea 0.5 0.2 1.5
Schizophrenia 2.4 1.6 0.5
scoliosis 0.4 0.5 -0.25
Sjögren syndrome 1.8 0.9 1
Sleep Apnea 1.8 1.1 0.64
Small Intestinal Bacterial Overgrowth (SIBO) 0.4 0.4
Stress / posttraumatic stress disorder 1.5 1.6 -0.07
Systemic Lupus Erythematosus 2.2 1.7 0.29
Tic Disorder 1 1.2 -0.2
Tourette syndrome 0.5 0.5
Type 1 Diabetes 1.4 0.2 6
Type 2 Diabetes 3.8 3.9 -0.03
Ulcerative colitis 0.9 3.4 -2.78
Unhealthy Ageing 2.1 1.6 0.31

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [44.222.64 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.222.64 ]